Nicolas Fischer, CEO introduces Light Chain Bioscience | Novimmune SA.
Edesa Biotech enrolls First Patient in COVID-19 Study of NI-0101 / EB05 (TLR4 anytibody).
Light Chain Bioscience has entered into two research collaborations and worldwide licensing agreements with Discoveric bio group.
Milestones achieved under research collaboration with LamKap Bio.
Antibodies being used as a T-cell targeting system to wipe out cancer cells.
